Compare · BAX vs BDX
BAX vs BDX
Side-by-side comparison of Baxter International Inc. (BAX) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BAX and BDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 4.2x BAX ($10.01B).
- Over the past year, BAX is down 37.2% and BDX is down 12.3% - BDX leads by 24.9 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 5 for BAX).
- Both have 25 recent analyst ratings on file.
- Company
- Baxter International Inc.
- Becton Dickinson and Company
- Price
- $19.37+0.05%
- $151.22+1.14%
- Market cap
- $10.01B
- $41.65B
- 1M return
- +14.14%
- +4.55%
- 1Y return
- -37.21%
- -12.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 10
- Recent ratings
- 25
- 25
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BAX
- SVP, Interim CFO, CAO & Cntrlr Zielinski Anita A was granted 13,426 shares, increasing direct ownership by 29% to 59,714 units (SEC Form 4)
- President, Adv. Surgery Wallace Steven P. covered exercise/tax liability with 153 shares, decreasing direct ownership by 0.22% to 70,128 units (SEC Form 4)
- President, CCS Teaff James covered exercise/tax liability with 321 shares, decreasing direct ownership by 1% to 31,063 units (SEC Form 4)
- SEC Form SD filed by Baxter International Inc.
- Baxter downgraded by Citigroup with a new price target
- SEC Form S-8 filed by Baxter International Inc.
- Baxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Director Wilkes David S. was granted 12,836 shares, increasing direct ownership by 53% to 37,076 units (SEC Form 4)
- Director Wendell Amy Mcbride was granted 12,836 shares, increasing direct ownership by 41% to 44,235 units (SEC Form 4)
- Director Schlichting Nancy M was granted 12,836 shares, increasing direct ownership by 58% to 34,994 units (SEC Form 4)
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional